Ucello Therapeutics Completes RMB 160 Million Series A Financing Led by Matrix Partners China

On February 10, Ucello Therapeutics (referred to as "Ucello") announced that it had recently completed its Series A round of financing worth 160 million RMB, led exclusively by Matrix Partners China.

This round of financing will be mainly used for further improving UCELLO's unique universal CAR-T cell technology platform CBT-X20, preparing for the China and US IND application of its core product AT19, and the construction of the company’s research, development, and production facilities.

UCELLO is a startup biotechnology company focused on the development and commercialization of universal cell therapy products. It was established in December 2020 at CHENGDU BIO-TOWN GROUP. Based on its self-developed and continuously optimized universal CAR-T cell technology platform, CBT-X20, UCELLO has developed multiple "off-the-shelf" cell therapy products targeting unmet clinical needs in the field of malignant tumors, which are expected to fundamentally change the current CAR-T cell therapy landscape.